HC Wainwright Affirms Buy Rating on Lineage Cell Therapeutics Inc. (LCTX) amid Type 1 Diabetes Push [Yahoo! Finance]
Lineage Cell Therapeutics, Inc. (LCTX)
Company Research
Source: Yahoo! Finance
reiterated a ‘Buy' rating on the stock and a $9 price target, buoyed by the stock's impressive run year to date. HC Wainwright Affirms Buy Rating on Lineage Cell Therapeutics Inc. (LCTX) amid Type 1 Diabetes Push Copyright: nexusplexus / 123RF Stock Photo In addition, the buy rating affirms the research firm's confidence in the company's long-term prospects as it pursues a new initiative in treating Type 1 diabetes. Lineage Cell Therapeutics has already announced plans to develop a new islet cell transplant program for Type 1 Diabetes. The program is to leverage the company's extensive experience in embryonic and cell line manipulation. According to HC Wainwright, the proposed Type 1 initiative could ultimately impact hypofunctional cell development, leading to functional cures based on early data from islets. Lineage Cell Therapeutics Inc. (NYSE:LCTX) is a clinical-stage biotechnology company that develops and manufactures specialized, “off-the-shelf” cell therapies to trea
Show less
Read more
Impact Snapshot
Event Time:
LCTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LCTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LCTX alerts
High impacting Lineage Cell Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LCTX
News
- Lineage Cell Therapeutics: OpRegen Makes It A Viable Speculative Buy [Seeking Alpha]Seeking Alpha
- Dimension Bio Announces Inaugural Clinical and Scientific Advisory BoardsPR Web
- Lineage Cell Therapeutics Inc (LCTX) Q3 2025 Earnings Call Highlights: Strategic Partnerships ... [Yahoo! Finance]Yahoo! Finance
- Lineage Cell Therapeutics GAAP EPS of -$0.13 misses by $0.10, revenue of $3.68M beats by $1.38M [Seeking Alpha]Seeking Alpha
- Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateBusiness Wire